Nipocalimab: a new entry in the dm+d dictionary
The NHS Business Services Authority has added nipocalimab to the dm+d dictionary (version 8.4.0). Nipocalimab is a neonatal Fc receptor (FcRn) antagonist — a specialist immunomodulator used to treat myasthenia gravis in patients with specific antibody profiles.
What is nipocalimab used for?
Nipocalimab is indicated for myasthenia gravis in patients who are anti-acetylcholine receptor (anti-AChR) or anti-muscle-specific kinase (anti-MuSK) antibody positive. It works by reducing pathogenic autoantibody levels, helping to restore neuromuscular function. Treatment is initiated in hospital settings with a loading phase of 300 mg subcutaneously weekly for 4 weeks, followed by maintenance dosing of 300 mg every 4 weeks.
Event medicine relevance
Nipocalimab is not appropriate for acute event-medicine use. It is a specialist therapy requiring hospital initiation, baseline immunological assessment, and ongoing monitoring by specialist teams. However, event medical responders may encounter patients on nipocalimab at events. Key points:
- Patients should carry a treatment summary and alert responders to their diagnosis and current therapy.
- Any acute myasthenic crisis requires immediate hospital conveyance and specialist neurology input.
- Responders should not initiate or adjust nipocalimab in the field.
Key cautions and interactions
Because nipocalimab is an immunomodulator, several important considerations apply:
- Serious infections: Patients are at increased risk of serious and opportunistic infections; active serious infection is a contraindication.
- Live vaccines: Avoid during and shortly after treatment due to reduced efficacy and increased risk of vaccine strain disease.
- Other immunosuppressants: Additive immunosuppression risk if combined with other immunosuppressive therapies.
- Hypersensitivity: Anaphylaxis and serious hypersensitivity reactions are possible; patients with known hypersensitivity to nipocalimab or excipients must not receive it.
- Pregnancy and breast-feeding: Limited data; specialist advice is required.
Patients with recurrent or chronic infections, hepatic impairment, renal impairment, or immunocompromise require specialist assessment before initiation.
Further information
For full prescribing guidance, consult the BNF and NICE. Always verify current guidance with the patient’s specialist team before any clinical decision.
View the full NHS BSA dm+d dictionary.